Amarin: Or, The Curious Case of the Single Drug

There are, admittedly, a few points in Amarin’s favor. The balance sheet, for instance, is…unburdened. No long-term debt, a cash reserve of nearly $135 million, and short-term investments totaling just under $168 million. This suggests a certain financial robustness, a capacity to sustain operations for a while. (Though, one must always remember that money, like time, is a relentlessly flowing river, and even the most substantial reserves eventually erode. It’s a fundamental principle of the universe, really.) In 2025, Vascepa managed to generate nearly $183 million in revenue. And the aforementioned restructuring has, at least on paper, reduced costs. Management anticipates positive free cash flow in 2026. A debt-free company with positive cash flow is, under normal circumstances, a mildly encouraging sign.







